In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression
- PMID: 17534577
- DOI: 10.1007/s10637-007-9060-9
In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression
Abstract
Aim of the study: mRNA expression of genes involved in the mechanism of action of pemetrexed was correlated with in vitro chemosensitivity of freshly explanted human tumor specimens.
Experimental design: Chemosensitivity to pemetrexed was studied in soft-agar. Multiplex rtPCR experiments for reduced folate carrier (RFC), folate receptor-alpha (FR-alpha), folylpolyglutamate synthetase (FPGS), thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), mrp4, and mrp5 were performed in parallel. Correlations, threshold optimization, sensitivity, specificity, and efficiency were analyzed using the appropriate statistical methodologies.
Results: In 61 samples, low levels of TS, GARFT, DHFR, and mrp4 gene expression significantly correlated with chemosensitivity to pemetrexed. Optimization analyses demonstrated threshold values of 144 copies for TS and six copies for mrp4 relative to 10(4) copies of beta-actin.
Conclusions: These results form a rational basis for the design of clinical trials to evaluate the expression of these enzymes as predictors for treatment outcome.
Similar articles
-
Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.J Thorac Oncol. 2013 May;8(5):644-53. doi: 10.1097/JTO.0b013e318287c224. J Thorac Oncol. 2013. PMID: 23449276
-
Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.Int J Clin Pharmacol Ther. 2005 Dec;43(12):567-9. doi: 10.5414/cpp43567. Int J Clin Pharmacol Ther. 2005. PMID: 16372519 No abstract available.
-
A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):832-8. doi: 10.1158/1078-0432.CCR-05-0295. Clin Cancer Res. 2006. PMID: 16467096 Clinical Trial.
-
Molecular, biochemical, and cellular pharmacology of pemetrexed.Semin Oncol. 2002 Dec;29(6 Suppl 18):3-17. doi: 10.1053/sonc.2002.37461. Semin Oncol. 2002. PMID: 12571805 Review.
-
Translational research with pemetrexed in breast cancer.Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):66-9. Oncology (Williston Park). 2004. PMID: 15655941 Review.
Cited by
-
Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed.Mol Cancer Ther. 2013 Oct;12(10):2248-60. doi: 10.1158/1535-7163.MCT-13-0172. Epub 2013 Jul 19. Mol Cancer Ther. 2013. PMID: 23873851 Free PMC article.
-
Pemetrexed versus vinorelbine treatment of advanced non-squamous non-small cell lung cancer in elderly patients.Mol Clin Oncol. 2013 May;1(3):553-557. doi: 10.3892/mco.2013.77. Epub 2013 Feb 18. Mol Clin Oncol. 2013. PMID: 24649210 Free PMC article.
-
Mechanisms of resistance to pemetrexed in non-small cell lung cancer.Transl Lung Cancer Res. 2019 Dec;8(6):1107-1118. doi: 10.21037/tlcr.2019.10.14. Transl Lung Cancer Res. 2019. PMID: 32010588 Free PMC article. Review.
-
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.J Exp Clin Cancer Res. 2010 Apr 27;29(1):38. doi: 10.1186/1756-9966-29-38. J Exp Clin Cancer Res. 2010. PMID: 20423465 Free PMC article. Clinical Trial.
-
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.Transl Lung Cancer Res. 2019 Jun;8(3):247-257. doi: 10.21037/tlcr.2019.04.19. Transl Lung Cancer Res. 2019. PMID: 31367538 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials